DPYSL2 DPYSL2 Biomarkers for Diagnosis of Chronic Hepatic Disease Based on Integrated Transcriptome Analysis and Use Thereof

摘要

The present invention relates to a biomarker for diagnosing chronic liver disease DPYSL2 based on integrated transcriptome analysis and its use, and more particularly, DPYSL2 biomarker selected through integrated transcriptome analysis and machine learning analysis for steatosis and nonalcoholic steatohepatitis patients It relates to a marker and a method for providing information on the diagnosis of chronic liver disease using the same. In the present invention, the DPYSL2 biomarker is finally selected using a process of selecting genes and feature selection through differentially expressed gene (DEG) analysis by performing integrated transcriptase analysis on steatosis and NASH patients. It was confirmed that the DPYSL2 biomarker of the present invention can be applied as a biomarker for diagnosing chronic liver disease.